Table 4. Annual costs and benefits over ten years of a conditional policy approach of all synthetic nucleic acids >50bp bought and sold in the EU (€ millions)
together, the results position the conditional mandatory pathway, particularly in the early years of implementation. This suggests that net societal benefits at lower upfront cost, or complementary approach, but with more accuracy of risk-based triggers, consistent
原图定位
